| 1 | Aspergillus Serologic Findings and Clinical Outcomes in Patients With BronchiectasisChest, 2025, 167, 975-992 | 0.8 | 30 | Citations (PDF) |
| 2 | Clinical Efficacy of Serum Antiglycopeptidolipid Core IgA Antibody Test for Screening Nontuberculous Mycobacterial Pulmonary Disease in BronchiectasisChest, 2025, 167, 1300-1310 | 0.8 | 4 | Citations (PDF) |
| 3 | Short-term stability of the sputum microbiota in bronchiectasis and cystic fibrosis | 1.6 | 0 | Citations (PDF) |
| 4 | Use of an extensively humanized mouse model to predict the risk of drug–drug interactions in patients receiving dexamethasone | 2.3 | 5 | Citations (PDF) |
| 5 | Viruses in bronchiectasis | 1.6 | 6 | Citations (PDF) |
| 6 | The<i>European Respiratory Journal</i>: our drive to thrive in ’25! | 6.5 | 0 | Citations (PDF) |
| 7 | Seroprevalence of<i>Bordetella pertussis</i>in patients with COPD in a UK cohort | 1.6 | 0 | Citations (PDF) |
| 8 | Viewpoint: a white paper for a greener design, conduct and reporting of clinical trials in respiratory medicine | 6.5 | 2 | Citations (PDF) |
| 9 | Unbreak my heart: macrolide cardiovascular benefits and safety in bronchiectasis | 6.5 | 1 | Citations (PDF) |
| 10 | Neutrophilic inflammation in bronchiectasis | 4.7 | 67 | Citations (PDF) |
| 11 | Trial Conduct, Baseline Characteristics, and Symptom Burden of Patients in the ARISE Study | 1.8 | 2 | Citations (PDF) |
| 12 | Dipeptidyl peptidase-1 inhibitors in bronchiectasis | 4.7 | 17 | Citations (PDF) |
| 13 | IL-33, inflammation and mucus in COPD: the final FRONTIER? | 6.5 | 4 | Citations (PDF) |
| 14 | Neutrophils in pleural infection: untapped potential for targeted therapeutics | 6.5 | 0 | Citations (PDF) |
| 15 | Investigating the impact of dipeptidyl peptidase-1 inhibition in humans using multi-omics | 4.4 | 4 | Citations (PDF) |
| 16 | Inflammatory and Mucociliary Dysfunction-Based Endotypes Across the Spectrum of Chronic Airway DiseasesChest, 2025, 168, 1317-1329 | 0.8 | 7 | Citations (PDF) |
| 17 | Effect of COVID-19 on Bronchiectasis Exacerbation Rates: A Retrospective U.S. Insurance Claims Study | 2.1 | 16 | Citations (PDF) |
| 18 | Prescribing preferences and availability of nebulisers and inhalers for inhaled medications in bronchiectasis: results of a specialist survey | 1.6 | 7 | Citations (PDF) |
| 19 | Primary Ciliary Dyskinesia: Integrating Genetics into Clinical Practice | 0.4 | 13 | Citations (PDF) |
| 20 | The preclinical and phase 1 development of the novel oral cathepsin C inhibitor BI 1291583 | 1.6 | 9 | Citations (PDF) |
| 21 | Eradication treatment forPseudomonas aeruginosainfection in adults with bronchiectasis: a systematic review and meta-analysis | 4.7 | 35 | Citations (PDF) |
| 22 | The Efficacy and Safety of Inhaled Antibiotics for the Treatment of Bronchiectasis in Adults | 0.8 | 58 | Citations (PDF) |
| 23 | Sputum metagenomics of people with bronchiectasis | 1.6 | 6 | Citations (PDF) |
| 24 | Digital technologies in bronchiectasis physiotherapy services: a survey of patients and physiotherapists in a UK centre | 1.6 | 3 | Citations (PDF) |
| 25 | Reply to Chen
et al.
: Reexamining Chronic Obstructive Pulmonary Disease in Bronchiectasis: Elucidating Overdiagnosis and Outcomes from EMBARC’s ROSE Criteria | 5.0 | 0 | Citations (PDF) |
| 26 | Bronchiectasis-associated infections and outcomes in a large, geographically diverse electronic health record cohort in the United States | 1.5 | 6 | Citations (PDF) |
| 27 | Ciliopathy patient variants reveal organelle-specific functions for TUBB4B in axonemal microtubules | 26.1 | 48 | Citations (PDF) |
| 28 | Ecological and evolutionary mechanisms driving within-patient emergence of antimicrobial resistance | 58.2 | 59 | Citations (PDF) |
| 29 | Bronchiectasis management in adults: state of the art and future directions | 6.5 | 106 | Citations (PDF) |
| 30 | Williams–Campbell syndrome case series and discordant twins | 1.6 | 1 | Citations (PDF) |
| 31 | The Precision Medicine Era of Bronchiectasis | 5.0 | 32 | Citations (PDF) |
| 32 | Rethinking bronchiectasis as an inflammatory disease | 15.9 | 83 | Citations (PDF) |
| 33 | EMBARCing on a new era for bronchiectasis: a review series for the Seventh World Bronchiectasis Conference | 4.7 | 3 | Citations (PDF) |
| 34 | Pathophysiology and genomics of bronchiectasis | 4.7 | 56 | Citations (PDF) |
| 35 | Biomarkers in bronchiectasis | 4.7 | 34 | Citations (PDF) |
| 36 | Postinfectious Pulmonary Complications: Establishing Research Priorities to Advance the Field: An Official American Thoracic Society Workshop Report | 2.1 | 24 | Citations (PDF) |
| 37 | A systematic literature review of the clinical and socioeconomic burden of bronchiectasis | 4.7 | 34 | Citations (PDF) |
| 38 | Neutrophil serine proteases in cystic fibrosis: role in disease pathogenesis and rationale as a therapeutic target | 4.7 | 20 | Citations (PDF) |
| 39 | Bronchiectasis in Asia: a review of current status and challenges | 4.7 | 21 | Citations (PDF) |
| 40 | Safety profile of drugs used in non-cystic fibrosis bronchiectasis: a narrative review | 1.4 | 4 | Citations (PDF) |
| 41 | Airway clearance treatments in bronchiectasis: feasibility of linking survey results to registry data and a survey of patients’ and physiotherapists’ practices | 1.6 | 7 | Citations (PDF) |
| 42 | Review of the British Thoracic Society Winter Meeting 23 November 2022 23–25 November 2022 | 3.4 | 1 | Citations (PDF) |
| 43 | Low Salivary Secretory Leukocyte Protease Inhibitor Levels Are Related to Airway Pseudomonas aeruginosa Infection in BronchiectasisChest, 2023, 164, 323-326 | 0.8 | 2 | Citations (PDF) |
| 44 | Benefit−risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis | 1.6 | 10 | Citations (PDF) |
| 45 | The Bronchiectasis Exacerbation Diary: a novel patient-reported outcome for non-cystic fibrosis bronchiectasis | 1.6 | 7 | Citations (PDF) |
| 46 | Basic, translational and clinical aspects of bronchiectasis in adults | 4.7 | 62 | Citations (PDF) |
| 47 | Respiratory Admissions Linked to Air Pollution in a Medium Sized City of the UK: A Case-crossover Study | 1.8 | 3 | Citations (PDF) |
| 48 | The Economic Burden of BronchiectasisChest, 2023, 164, 1396-1421 | 0.8 | 65 | Citations (PDF) |
| 49 | A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2 | 1.6 | 12 | Citations (PDF) |
| 50 | Inflammatory Molecular Endotypes in Bronchiectasis: A European Multicenter Cohort Study | 5.0 | 77 | Citations (PDF) |
| 51 | Bronchiectasis | 2.3 | 36 | Citations (PDF) |
| 52 | EFFICACY AND SAFETY OF DIPEPTIDYL PEPTIDASE-1 INHIBITION WITH BRENSOCATIB IN THE FREQUENT EXACERBATOR PHENOTYPE: A SUBGROUP ANALYSIS FROM THE WILLOW TRIALChest, 2023, 164, A4961-A4962 | 0.8 | 0 | Citations (PDF) |
| 53 | Dipeptidyl peptidase 1 inhibition as a potential therapeutic approach in neutrophil-mediated inflammatory disease | 3.3 | 49 | Citations (PDF) |
| 54 | High Frequency of Allergic Bronchopulmonary Aspergillosis in Bronchiectasis-COPD Overlap | 0.8 | 38 | Citations (PDF) |
| 55 | Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations | 15.9 | 281 | Citations (PDF) |
| 56 | Heterogeneity of treatment response in bronchiectasis clinical trials | 6.5 | 52 | Citations (PDF) |
| 57 | Sputum Proteomics in Nontuberculous Mycobacterial Lung DiseaseChest, 2022, 161, 1180-1191 | 0.8 | 16 | Citations (PDF) |
| 58 | Bronchiectasis and inhaled tobramycin: A literature review | 1.8 | 30 | Citations (PDF) |
| 59 | Intermittent prophylactic antibiotics for bronchiectasis | 1.7 | 6 | Citations (PDF) |
| 60 | Just breathe: a review of sex and gender in chronic lung disease | 4.7 | 87 | Citations (PDF) |
| 61 | Critical appraisal of international adult bronchiectasis guidelines using the AGREE II tool | 2.4 | 3 | Citations (PDF) |
| 62 | Characterization of Eosinophilic Bronchiectasis: A European Multicohort Study | 5.0 | 209 | Citations (PDF) |
| 63 | Neutrophil extracellular traps in chronic lung disease: implications for pathogenesis and therapy | 4.7 | 162 | Citations (PDF) |
| 64 | Bronchiectasis from 2012 to 2022 | 1.6 | 18 | Citations (PDF) |
| 65 | Comparison of different sets of immunological tests to identify treatable immunodeficiencies in adult bronchiectasis patients | 1.6 | 10 | Citations (PDF) |
| 66 | Endotyping Chronic Obstructive Pulmonary Disease, Bronchiectasis, and the “Chronic Obstructive Pulmonary Disease–Bronchiectasis Association” | 5.0 | 80 | Citations (PDF) |
| 67 | Multiple-Breath Washout Outcome Measures in Adults with Bronchiectasis | 2.1 | 13 | Citations (PDF) |
| 68 | Cardiovascular outcomes in patients with chronic kidney disease and COVID-19: a multi-regional data-linkage study | 6.5 | 18 | Citations (PDF) |
| 69 | A descriptive cohort study of withdrawal from inhaled corticosteroids in COPD patients | 2.3 | 4 | Citations (PDF) |
| 70 | COVID-19 follow-up programmes across Europe: an ERS END-COVID CRC survey | 6.5 | 11 | Citations (PDF) |
| 71 | Review of the British Thoracic Society Winter Meeting 2021, 24–26 November 2021 | 3.4 | 0 | Citations (PDF) |
| 72 | Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis | 2.1 | 22 | Citations (PDF) |
| 73 | Respiratory healthcare professionals’ views on long-term recommendations of interventions to prevent acute respiratory illnesses after the COVID-19 pandemic | 1.6 | 1 | Citations (PDF) |
| 74 | The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease | 4.4 | 198 | Citations (PDF) |
| 75 | A high-risk airway mycobiome is associated with frequent exacerbation and mortality in COPD | 6.5 | 81 | Citations (PDF) |
| 76 | Validation of the Bronchiectasis Impact Measure (BIM): a novel patient-reported outcome measure | 6.5 | 24 | Citations (PDF) |
| 77 | A Cluster Analysis of Bronchiectasis Patients Based on the Airway Immune ProfileChest, 2021, 159, 1758-1767 | 0.8 | 27 | Citations (PDF) |
| 78 | Efficacy and safety of TOBI Podhaler inPseudomonas aeruginosa-infected bronchiectasis patients: iBEST study | 6.5 | 52 | Citations (PDF) |
| 79 | Development of Drugs for Nontuberculous Mycobacterial DiseaseChest, 2021, 159, 537-543 | 0.8 | 26 | Citations (PDF) |
| 80 | Neutrophil dysfunction in bronchiectasis: an emerging role for immunometabolism | 6.5 | 51 | Citations (PDF) |
| 81 | European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis | 6.5 | 221 | Citations (PDF) |
| 82 | BronchUK: protocol for an observational cohort study and biobank in bronchiectasis | 1.6 | 9 | Citations (PDF) |
| 83 | Respiratory Mycoses in COPD and Bronchiectasis | 2.2 | 29 | Citations (PDF) |
| 84 | Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline | 6.5 | 189 | Citations (PDF) |
| 85 | Integrative microbiomics in bronchiectasis exacerbations | 22.6 | 204 | Citations (PDF) |
| 86 | Characteristics of bronchiectasis in Korea: First data from the Korean Multicentre Bronchiectasis Audit and Research Collaboration registry and comparison with other international registries | 2.7 | 73 | Citations (PDF) |
| 87 | The protective effect of SARS-CoV-2 antibodies in Scottish healthcare workers | 1.6 | 26 | Citations (PDF) |
| 88 | Pneumonia | 37.8 | 707 | Citations (PDF) |
| 89 | Psychometrics of health-related quality of life questionnaires in bronchiectasis: a systematic review and meta-analysis | 6.5 | 39 | Citations (PDF) |
| 90 | Clinical and research priorities for children and young people with bronchiectasis: an international roadmap | 1.6 | 48 | Citations (PDF) |
| 91 | The association between SARS-CoV-2 RT-PCR cycle threshold and mortality in a community cohort | 6.5 | 41 | Citations (PDF) |
| 92 | Patients’ perspectives on bronchiectasis: findings from a social media listening study | 1.6 | 12 | Citations (PDF) |
| 93 | Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report | 2.1 | 52 | Citations (PDF) |
| 94 | Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections | 4.7 | 34 | Citations (PDF) |
| 95 | The Impact of the COVID-19 Pandemic on Exacerbations and Symptoms in Bronchiectasis: A Prospective Study | 5.0 | 55 | Citations (PDF) |
| 96 | Pathophysiology of Bronchiectasis | 1.8 | 81 | Citations (PDF) |
| 97 | The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease | 15.9 | 115 | Citations (PDF) |
| 98 | The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study | 15.9 | 160 | Citations (PDF) |
| 99 | SPLUNC1 is a novel marker of disease severity and airway infection in bronchiectasis | 6.5 | 13 | Citations (PDF) |
| 100 | Exhaled volatile organic compounds and lung microbiome in COPD: a pilot randomised controlled trial | 1.6 | 11 | Citations (PDF) |
| 101 | Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study | 15.9 | 234 | Citations (PDF) |
| 102 | Inhaled Corticosteroids and the Lung Microbiome in COPD | 2.5 | 40 | Citations (PDF) |
| 103 | ROSE: radiology, obstruction, symptoms and exposure – a Delphi consensus definition of the association of COPD and bronchiectasis by the EMBARC Airways Working Group | 1.6 | 57 | Citations (PDF) |
| 104 | LTA4H rs2660845 association with montelukast response in early and late-onset asthma | 1.5 | 12 | Citations (PDF) |
| 105 | Associations between ambient air pollutants and hospital admissions: more needs to be done | 2.6 | 6 | Citations (PDF) |
| 106 | Thrombocytosis during Stable State Predicts Mortality in Bronchiectasis | 2.1 | 12 | Citations (PDF) |
| 107 | Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study | 15.9 | 604 | Citations (PDF) |
| 108 | What is important for people with nontuberculous mycobacterial disease? An EMBARC-ELF patient survey | 1.6 | 14 | Citations (PDF) |
| 109 | The immunomodulatory effects of macrolide antibiotics in respiratory disease | 1.9 | 121 | Citations (PDF) |
| 110 | An 18 year data-linkage study on the association between air pollution and acute limb ischaemia | 1.4 | 1 | Citations (PDF) |
| 111 | The impact of therapeutics on mortality in hospitalised patients with COVID-19: systematic review and meta-analyses informing the European Respiratory Society living guideline | 4.7 | 25 | Citations (PDF) |
| 112 | Precision medicine in bronchiectasis | 1.8 | 27 | Citations (PDF) |
| 113 | Validation of the COPD Assessment Test (CAT) as an Outcome Measure in BronchiectasisChest, 2020, 157, 815-823 | 0.8 | 38 | Citations (PDF) |
| 114 | Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020) | 4.7 | 94 | Citations (PDF) |
| 115 | Characteristics and outcomes of health and social care workers testing positive for SARS-CoV-2 in the Tayside region of Scotland | 6.5 | 9 | Citations (PDF) |
| 116 | Withdrawal of inhaled corticosteroids in COPD | 6.5 | 3 | Citations (PDF) |
| 117 | CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin | 1.6 | 35 | Citations (PDF) |
| 118 | ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial | 1.1 | 69 | Citations (PDF) |
| 119 | A membrane-depolarizing toxin substrate of the
Staphylococcus aureus
type VII secretion system mediates intraspecies competition | 5.2 | 100 | Citations (PDF) |
| 120 | A cuckoo COVID coincidence? | 6.5 | 0 | Citations (PDF) |
| 121 | Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials | 2.8 | 58 | Citations (PDF) |
| 122 | International Perspective on the New 2019 American Thoracic Society/Infectious Diseases Society of America Community-Acquired Pneumonia GuidelineChest, 2020, 158, 1912-1918 | 0.8 | 69 | Citations (PDF) |
| 123 | Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey | 3.7 | 39 | Citations (PDF) |
| 124 | Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis | 26.4 | 355 | Citations (PDF) |
| 125 | European Respiratory Society International Congress, Madrid, 2019: nontuberculous mycobacterial pulmonary disease highlights | 1.6 | 10 | Citations (PDF) |
| 126 | Multiple breath washout in bronchiectasis clinical trials: is it feasible? | 1.6 | 8 | Citations (PDF) |
| 127 | Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline | 6.5 | 110 | Citations (PDF) |
| 128 | Estimates of the ongoing need for social distancing and control measures post-“lockdown” from trajectories of COVID-19 cases and mortality | 6.5 | 63 | Citations (PDF) |
| 129 | Serum Desmosine Is Associated with Long-Term All-Cause and Cardiovascular Mortality in Bronchiectasis | 5.0 | 28 | Citations (PDF) |
| 130 | Sputum neutrophil elastase associates with microbiota andPseudomonas aeruginosain bronchiectasis | 6.5 | 74 | Citations (PDF) |
| 131 | Treatment of Community-Acquired Pneumonia in Immunocompromised AdultsChest, 2020, 158, 1896-1911 | 0.8 | 216 | Citations (PDF) |
| 132 | Variability in airway inflammation, symptoms, lung function and reliever use in asthma: anti-inflammatory reliever hypothesis and STIFLE study design | 1.6 | 5 | Citations (PDF) |
| 133 | Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies | 6.5 | 50 | Citations (PDF) |
| 134 | Increased Chitotriosidase Is Associated With Aspergillus and Frequent Exacerbations in South-East Asian Patients With BronchiectasisChest, 2020, 158, 512-522 | 0.8 | 21 | Citations (PDF) |
| 135 | Managing and preventing exacerbation of bronchiectasis | 2.4 | 13 | Citations (PDF) |
| 136 | Relationship between Symptoms, Exacerbations, and Treatment Response in Bronchiectasis | 5.0 | 53 | Citations (PDF) |
| 137 | Is bronchiectasis really a disease? | 4.7 | 17 | Citations (PDF) |
| 138 | Blood neutrophil counts are associated with exacerbation frequency and mortality in COPD | 2.8 | 74 | Citations (PDF) |
| 139 | Sputum neutrophil elastase in bronchiectasis: a Southern European cohort study | 6.5 | 34 | Citations (PDF) |
| 140 | Development and initial validation of the bronchiectasis exacerbation and symptom tool (BEST) | 2.8 | 28 | Citations (PDF) |
| 141 | Inhaled aztreonam improves symptoms of cough and sputum production in patients with bronchiectasis: apost hocanalysis of the AIR-BX studies | 6.5 | 36 | Citations (PDF) |
| 142 | Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO® Trials | 2.7 | 13 | Citations (PDF) |
| 143 | Clinical endotypes of exacerbation are associated with differences in microbial composition and diversity in COPD | 6.5 | 24 | Citations (PDF) |
| 144 | Genetic and pharmacological relationship between P-glycoprotein and increased cardiovascular risk associated with clarithromycin prescription: An epidemiological and genomic population-based cohort study in Scotland, UK | 4.6 | 6 | Citations (PDF) |
| 145 | Providing answers to respiratory patients' questions during COVID-19 | 1.8 | 1 | Citations (PDF) |
| 146 | Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry | 9.7 | 203 | Citations (PDF) |
| 147 | Pregnancy Zone Protein Is Associated with Airway Infection, Neutrophil Extracellular Trap Formation, and Disease Severity in Bronchiectasis | 5.0 | 78 | Citations (PDF) |
| 148 | Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection | 3.5 | 13 | Citations (PDF) |
| 149 | Evaluation of active neutrophil elastase in sputum of bronchiectasis and cystic fibrosis patients: A comparison among different techniques | 1.9 | 24 | Citations (PDF) |
| 150 | Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis | 15.9 | 183 | Citations (PDF) |
| 151 | Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1) | 1.9 | 12 | Citations (PDF) |
| 152 | The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis | 15.9 | 114 | Citations (PDF) |
| 153 | Challenges in severe community-acquired pneumonia: a point-of-view review | 3.5 | 156 | Citations (PDF) |
| 154 | Bronchiectasis Guidelines-Recommendations Into Practice | 1.0 | 1 | Citations (PDF) |
| 155 | A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation | 6.5 | 88 | Citations (PDF) |
| 156 | Airway Bacterial Load and Inhaled Antibiotic Response in Bronchiectasis | 5.0 | 112 | Citations (PDF) |
| 157 | Pulmonary rehabilitation after exacerbation of bronchiectasis: a pilot randomized controlled trial | 1.5 | 22 | Citations (PDF) |
| 158 | Bronchiectasis insanity: Doing the same thing over and over again and expecting different results? | 0.3 | 23 | Citations (PDF) |
| 159 | The economic burden of bronchiectasis – known and unknown: a systematic review | 1.5 | 87 | Citations (PDF) |
| 160 | A systematic review of pharmacotherapeutic clinical trial end-points for bronchiectasis in adults | 4.7 | 37 | Citations (PDF) |
| 161 | Personalised anti-inflammatory therapy for bronchiectasis and cystic fibrosis: selecting patients for controlled trials of neutrophil elastase inhibition | 1.6 | 28 | Citations (PDF) |
| 162 | Recommendations for travelling with bronchiectasis: a joint ELF/EMBARC/ERN-Lung collaboration | 1.6 | 4 | Citations (PDF) |
| 163 | British Thoracic Society Guideline for bronchiectasis in adults | 3.4 | 495 | Citations (PDF) |
| 164 | The microbiome in bronchiectasis | 4.7 | 102 | Citations (PDF) |
| 165 | Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review | 2.8 | 27 | Citations (PDF) |
| 166 | The impact of certain underlying comorbidities on the risk of developing hospitalised pneumonia in England | 1.9 | 23 | Citations (PDF) |
| 167 | Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals | 2.1 | 659 | Citations (PDF) |
| 168 | Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials | 15.9 | 207 | Citations (PDF) |
| 169 | Economic burden of bronchiectasis in Germany | 6.5 | 64 | Citations (PDF) |
| 170 | Distinct “Immunoallertypes” of Disease and High Frequencies of Sensitization in Non–Cystic Fibrosis Bronchiectasis | 5.0 | 89 | Citations (PDF) |
| 171 | Bronchiectasis Guidelines-Recommendations Into Practice | 1.0 | 6 | Citations (PDF) |
| 172 | Bronchiectasis: new therapies and new perspectives | 15.9 | 195 | Citations (PDF) |
| 173 | Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review | 1.8 | 136 | Citations (PDF) |
| 174 | Identification of Pseudomonas aeruginosa and airway bacterial colonization by an electronic nose in bronchiectasis | 1.8 | 31 | Citations (PDF) |
| 175 | The independent contribution ofPseudomonas aeruginosainfection to long-term clinical outcomes in bronchiectasis | 6.5 | 230 | Citations (PDF) |
| 176 | Characterization of the “Frequent Exacerbator Phenotype” in Bronchiectasis | 5.0 | 338 | Citations (PDF) |
| 177 | The BRICS (Bronchiectasis Radiologically Indexed CT Score)Chest, 2018, 153, 1177-1186 | 0.8 | 71 | Citations (PDF) |
| 178 | Macrolides, mucoactive drugs and adherence for the management of bronchiectasis | 6.5 | 7 | Citations (PDF) |
| 179 | Assessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational study using the Clinical Practice Research Datalink (CPRD) | 2.8 | 24 | Citations (PDF) |
| 180 | Oral versus inhaled antibiotics for bronchiectasis | 1.7 | 14 | Citations (PDF) |
| 181 | Macrolide antibiotics for bronchiectasis | 1.7 | 73 | Citations (PDF) |
| 182 | Neutrophil extracellular traps are associated with disease severity and microbiota diversity in patients with chronic obstructive pulmonary disease | 4.4 | 287 | Citations (PDF) |
| 183 | Genetic mannose binding lectin deficiency is associated with airway microbiota diversity and reduced exacerbation frequency in COPD | 3.4 | 33 | Citations (PDF) |
| 184 | ERS syllabus for postgraduate training in respiratory infections: a guide for comprehensive training | 1.8 | 1 | Citations (PDF) |
| 185 | Circulating desmosine as a biomarker of azithromycin treatment response: apost hocanalysis of the COLUMBUS randomised controlled trial | 1.6 | 2 | Citations (PDF) |
| 186 | Bronchiectasis | 37.8 | 327 | Citations (PDF) |
| 187 | A comprehensive approach to lung function in bronchiectasis | 1.8 | 90 | Citations (PDF) |
| 188 | The effect of changes to GOLD severity stage on long term morbidity and mortality in COPD | 2.8 | 17 | Citations (PDF) |
| 189 | A systematic review of clinical trial registration in major respiratory journals 2010–2018 | 6.5 | 2 | Citations (PDF) |
| 190 | How to Process Sputum Samples and Extract Bacterial DNA for Microbiota Analysis | 3.2 | 39 | Citations (PDF) |
| 191 | Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity | 46.9 | 484 | Citations (PDF) |
| 192 | “The missing ingredient”: the patient perspective of health related quality of life in bronchiectasis: a qualitative study | 1.5 | 40 | Citations (PDF) |
| 193 | Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis | 1.5 | 229 | Citations (PDF) |
| 194 | The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions | 6.5 | 210 | Citations (PDF) |
| 195 | Burden and risk factors forPseudomonas aeruginosacommunity-acquired pneumonia: a multinational point prevalence study of hospitalised patients | 6.5 | 196 | Citations (PDF) |
| 196 | Bronchiectasis: a case-based approach to investigation and management | 4.7 | 42 | Citations (PDF) |
| 197 | A qualitative synthesis of gastro-oesophageal reflux in bronchiectasis: Current understanding and future risk | 1.8 | 43 | Citations (PDF) |
| 198 | The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol | 3.1 | 13 | Citations (PDF) |
| 199 | Why, when and how to investigate primary ciliary dyskinesia in adult patients with bronchiectasis | 3.1 | 32 | Citations (PDF) |
| 200 | Continuous versus intermittent antibiotics for bronchiectasis | 1.7 | 10 | Citations (PDF) |
| 201 | Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia | 1.8 | 17 | Citations (PDF) |
| 202 | Immunological corollary of the pulmonary mycobiome in bronchiectasis: the CAMEB study | 6.5 | 154 | Citations (PDF) |
| 203 | The impact of acute air pollution fluctuations on bronchiectasis pulmonary exacerbation: a case-crossover analysis | 6.5 | 67 | Citations (PDF) |
| 204 | Severe Paediatric Asthma Collaborative in Europe (SPACE): protocol for a European registry | 1.8 | 14 | Citations (PDF) |
| 205 | Additional important research priorities for bronchiectasis in China | 6.5 | 0 | Citations (PDF) |
| 206 | Disbiosis microbiana en las bronquiectasias y la fibrosis quística | 1.0 | 1 | Citations (PDF) |
| 207 | Bronchiectasis Rheumatoid Overlap Syndrome Is an Independent Risk Factor for Mortality in Patients With BronchiectasisChest, 2017, 151, 1247-1254 | 0.8 | 110 | Citations (PDF) |
| 208 | The microbiome in respiratory medicine: current challenges and future perspectives | 6.5 | 234 | Citations (PDF) |
| 209 | Anti-Pseudomonas aeruginosa IgG antibodies and chronic airway infection in bronchiectasis | 1.8 | 28 | Citations (PDF) |
| 210 | The heterogeneity of systemic inflammation in bronchiectasis | 1.8 | 74 | Citations (PDF) |
| 211 | Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis | 5.0 | 372 | Citations (PDF) |
| 212 | A Randomized Controlled Trial of Atorvastatin in Patients With Bronchiectasis Infected With Pseudomonas AeruginosaChest, 2017, 152, 368-378 | 0.8 | 42 | Citations (PDF) |
| 213 | Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research | 6.5 | 382 | Citations (PDF) |
| 214 | Severe Pneumococcal Pneumonia Causes Acute Cardiac Toxicity and Subsequent Cardiac Remodeling | 5.0 | 154 | Citations (PDF) |
| 215 | Microbial Dysbiosis in Bronchiectasis and Cystic Fibrosis | 1.0 | 1 | Citations (PDF) |
| 216 | New therapies for the prevention and treatment of exacerbations of bronchiectasis | 1.4 | 10 | Citations (PDF) |
| 217 | Management of chronic airway diseases: What can we learn from real-life data? | 1.4 | 3 | Citations (PDF) |
| 218 | Raising awareness of bronchiectasis in primary care: overview of diagnosis and management strategies in adults | 2.3 | 45 | Citations (PDF) |
| 219 | Bronchiectasis: Phenotyping a Complex Disease | 1.4 | 28 | Citations (PDF) |
| 220 | Patient participation in ERS guidelines and research projects: the EMBARC experience | 1.8 | 23 | Citations (PDF) |
| 221 | Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia | 6.5 | 6 | Citations (PDF) |
| 222 | European Respiratory Society guidelines for the management of adult bronchiectasis | 6.5 | 1,225 | Citations (PDF) |
| 223 | The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC): experiences from a successful ERS Clinical Research Collaboration | 1.8 | 38 | Citations (PDF) |
| 224 | Profile of the ProAxsis active neutrophil elastase immunoassay for precision medicine in chronic respiratory disease | 2.3 | 12 | Citations (PDF) |
| 225 | Standardised classification of the aetiology of bronchiectasis using an objective algorithm | 6.5 | 90 | Citations (PDF) |
| 226 | High endocan levels are associated with the need for mechanical ventilation among patients with severe sepsis | 6.5 | 10 | Citations (PDF) |
| 227 | The past decade in bench research into pulmonary infectious diseases: What do clinicians need to know? | 2.7 | 9 | Citations (PDF) |
| 228 | Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice | 2.3 | 61 | Citations (PDF) |
| 229 | Role of cephalosporins in the era ofClostridium difficileinfection | 2.1 | 70 | Citations (PDF) |
| 230 | Withdrawal of ICS treatment in primary care: A practical guide | 0.1 | 4 | Citations (PDF) |
| 231 | Short duration of antibiotic therapy in hospitalized patients with community-acquired pneumonia: results from the CAPO International Cohort Study | 0.0 | 1 | Citations (PDF) |
| 232 | Using cluster analysis of cytokines to identify patterns of inflammation in hospitalized patients with community-acquired pneumonia: a pilot study. | 0.0 | 16 | Citations (PDF) |
| 233 | A new free-cost e-service supporting clinicians to manage their difficult-to-treat tuberculosis cases | 1.0 | 0 | Citations (PDF) |
| 234 | Short duration of antibiotic therapy in hospitalized patients with
community-acquired pneumonia: results from the CAPO International Cohort Study | 0.0 | 0 | Citations (PDF) |
| 235 | Correlation of Obesity With Outcomes in Hospitalized Patients With Community-Acquired Pneumonia: Results From the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study | 0.7 | 0 | Citations (PDF) |
| 236 | Characterizing Non-Tuberculous Mycobacteria Infection in Bronchiectasis | 3.2 | 83 | Citations (PDF) |
| 237 |
Pseudomonas aeruginosa
resistance patterns and clinical outcomes in hospitalized exacerbations of COPD | 2.7 | 47 | Citations (PDF) |
| 238 | Quality standards for the management of bronchiectasis in Italy: a national audit | 6.5 | 39 | Citations (PDF) |
| 239 | Evaluation of serum inflammatory biomarkers as predictors of treatment outcome in pulmonary tuberculosis | 1.0 | 16 | Citations (PDF) |
| 240 | The Modern Diagnostic Approach to Community-Acquired Pneumonia in Adults | 1.8 | 16 | Citations (PDF) |
| 241 | Cardiovascular disease as a complication of community-acquired pneumonia | 1.4 | 57 | Citations (PDF) |
| 242 | Diagnostic challenges of bronchiectasis | 1.8 | 33 | Citations (PDF) |
| 243 | Risk factors for Clostridium difficile infection in hospitalized patients with community-acquired pneumonia | 2.5 | 70 | Citations (PDF) |
| 244 | Clinical phenotypes in bronchiectasis: right on track to develop precision medicine in respiratory diseases | 1.0 | 1 | Citations (PDF) |
| 245 | A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults | 1.5 | 77 | Citations (PDF) |
| 246 | Global impact of bronchiectasis and cystic fibrosis | 1.8 | 75 | Citations (PDF) |
| 247 | Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis | 2.0 | 79 | Citations (PDF) |
| 248 | Characterization of bronchiectasis in the elderly | 1.8 | 38 | Citations (PDF) |
| 249 | Empirical Coverage of Methicillin-ResistantStaphylococcus aureusin Community-Acquired Pneumonia: Those Who Do Not Remember the Past Are Doomed to Repeat It | 3.7 | 12 | Citations (PDF) |
| 250 | Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study | 15.9 | 293 | Citations (PDF) |
| 251 | Review of the British Thoracic Society Winter Meeting 2015, 2–4 December, London, UK | 3.4 | 0 | Citations (PDF) |
| 252 | Community-acquired pneumonia related to intracellular pathogens | 3.5 | 113 | Citations (PDF) |
| 253 | Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration | 6.5 | 195 | Citations (PDF) |
| 254 | Airway Mucin 2 Is Decreased in Patients with Severe Chronic Obstructive Pulmonary Disease with Bacterial Colonization | 2.1 | 24 | Citations (PDF) |
| 255 | The generalizability of bronchiectasis randomized controlled trials: A multicentre cohort study | 1.8 | 29 | Citations (PDF) |
| 256 | Clinical phenotypes in adult patients with bronchiectasis | 6.5 | 261 | Citations (PDF) |
| 257 | The EMBARC European Bronchiectasis Registry: protocol for an international observational study | 1.6 | 183 | Citations (PDF) |
| 258 | The type VII secretion system of Staphylococcus aureus secretes a nuclease toxin that targets competitor bacteria | 9.9 | 279 | Citations (PDF) |
| 259 | Clinical Tuberculosis | 1.8 | 0 | Citations (PDF) |
| 260 | Empirical Antibiotic Treatment for Community-acquired Pneumonia | 0.8 | 0 | Citations (PDF) |
| 261 | Antibiotic prophylaxis is ineffective in preventing pneumonia post-stroke | 0.5 | 3 | Citations (PDF) |
| 262 | No Strong Relationship Between Components of the Lectin Pathway of Complement and Susceptibility to Pulmonary Tuberculosis | 2.6 | 21 | Citations (PDF) |
| 263 | Review of the British Thoracic Society Winter Meeting 2014, 3-5 December, London, UK | 3.4 | 1 | Citations (PDF) |
| 264 | Secreted mucins and airway bacterial colonization in non‐CF bronchiectasis | 2.7 | 50 | Citations (PDF) |
| 265 | Doing science: how to get credit for your scientific work | 1.8 | 1 | Citations (PDF) |
| 266 | Outcomes in patients with community-acquired pneumonia admitted to the intensive care unit | 1.8 | 31 | Citations (PDF) |
| 267 | Management of bronchiectasis in adults | 6.5 | 269 | Citations (PDF) |
| 268 | Renal replacement therapy in Scottish critical care units: A national audit of practices | 1.0 | 1 | Citations (PDF) |
| 269 | Challenges in the development of new therapies for bronchiectasis | 1.9 | 23 | Citations (PDF) |
| 270 | Chromogranin A levels and mortality in patients with severe sepsis | 1.2 | 11 | Citations (PDF) |
| 271 | Etiology of Non–Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity | 2.1 | 288 | Citations (PDF) |
| 272 | Bronchiectasis in adults: epidemiology, assessment of severity and prognosis | 0.4 | 2 | Citations (PDF) |
| 273 | Community-acquired severity prediction—what are we predicting and why? | 0.3 | 1 | Citations (PDF) |
| 274 | Defining severity in non-cystic fibrosis bronchiectasis | 1.7 | 18 | Citations (PDF) |
| 275 | Heterogeneity in ess transcriptional organization and variable contribution of the Ess/Type VII protein secretion system to virulence across closely related Staphylocccus aureus strains | 1.8 | 109 | Citations (PDF) |
| 276 | The role of neutrophils in cystic fibrosis | 1.4 | 88 | Citations (PDF) |
| 277 | Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis | 2.8 | 49 | Citations (PDF) |
| 278 | Reply to Corrao et al | 3.7 | 1 | Citations (PDF) |
| 279 | Review of the British Thoracic Society Winter Meeting 2013, 4–6 December, London, UK | 3.4 | 1 | Citations (PDF) |
| 280 | Simplification of the IDSA/ATS criteria for severe CAP using meta-analysis and observational data | 6.5 | 72 | Citations (PDF) |
| 281 | Healthcare-Associated Pneumonia Does Not Accurately Identify Potentially Resistant Pathogens: A Systematic Review and Meta-Analysis | 3.7 | 244 | Citations (PDF) |
| 282 | COPD and Bronchiectasis: Phenotype, Endotype or Co-morbidity? | 1.4 | 44 | Citations (PDF) |
| 283 | Reply to Livorsi and Eckerle | 3.7 | 1 | Citations (PDF) |
| 284 | A multidisciplinary intervention to reduce antibiotic duration in lower respiratory tract infections | 2.1 | 37 | Citations (PDF) |
| 285 | Serum Ficolin-2 in Hospitalised Patients with Community-Acquired Pneumonia | 2.6 | 11 | Citations (PDF) |
| 286 | The Bronchiectasis Severity Index. An International Derivation and Validation Study | 5.0 | 1,009 | Citations (PDF) |
| 287 | Parapneumonic effusions: epidemiology and predictors of pleural infection | 0.5 | 5 | Citations (PDF) |
| 288 | Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy? | 3.4 | 114 | Citations (PDF) |
| 289 | Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial | 15.9 | 86 | Citations (PDF) |
| 290 | A prospective cohort study of the use of domiciliary intravenous antibiotics in bronchiectasis | 2.3 | 23 | Citations (PDF) |
| 291 | Hospitalized AECOPD Patients Not Treated With Antibiotic Have Higher Rates of 1-Year Pneumonia Related Hospitalization | 0.8 | 0 | Citations (PDF) |
| 292 | An evaluation of clinical stability criteria to predict hospital course in community-acquired pneumonia | 3.5 | 33 | Citations (PDF) |
| 293 | Risk Factors for Aspiration in Community-acquired Pneumonia: Analysis of a Hospitalized UK Cohort | 1.4 | 134 | Citations (PDF) |
| 294 | Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis | 2.0 | 180 | Citations (PDF) |
| 295 | Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study | 15.9 | 88 | Citations (PDF) |
| 296 | Predictors of Mortality in Hospitalized Adults with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. A Systematic Review and Meta-analysis | 2.1 | 241 | Citations (PDF) |
| 297 | Severity assessment scores to guide empirical use of antibiotics in community acquired pneumonia | 15.9 | 34 | Citations (PDF) |
| 298 | Symptoms of airway reflux predict exacerbations and quality of life in bronchiectasis | 1.8 | 54 | Citations (PDF) |
| 299 | Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis | 3.4 | 145 | Citations (PDF) |
| 300 | Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective: Table 1 | 3.4 | 143 | Citations (PDF) |
| 301 | Eight-weekly intravenous antibiotics is beneficial in severe bronchiectasis | 0.3 | 31 | Citations (PDF) |
| 302 | Does an interferon-gamma release assay change practice in possible latent tuberculosis? | 0.3 | 4 | Citations (PDF) |
| 303 | Author response—vitamin D deficiency and systemic inflammation in bronchiectasis | 3.4 | 1 | Citations (PDF) |
| 304 | Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies | 0.2 | 120 | Citations (PDF) |
| 305 | Obesity is associated with improved survival in community-acquired pneumonia | 6.5 | 69 | Citations (PDF) |
| 306 | Human L-Ficolin (Ficolin-2) and Its Clinical Significance | 5.8 | 90 | Citations (PDF) |
| 307 | Diagnostik bei Verdacht auf unteren Atemwegsinfekt und Therapieresistenz | 0.2 | 0 | Citations (PDF) |
| 308 | Contact tracing in pulmonary and non-pulmonary tuberculosis | 0.3 | 20 | Citations (PDF) |
| 309 | Can we use severity assessment tools to increase outpatient management of community-acquired pneumonia? | 2.4 | 25 | Citations (PDF) |
| 310 | Short- and Long-Term Antibiotic Treatment Reduces Airway and Systemic Inflammation in Non–Cystic Fibrosis Bronchiectasis | 5.0 | 389 | Citations (PDF) |
| 311 | Physician judgement is a crucial adjunct to pneumonia severity scores in low-risk patients | 6.5 | 42 | Citations (PDF) |
| 312 | Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia—a propensity-adjusted analysis | 3.5 | 50 | Citations (PDF) |
| 313 | Factors associated with severe illness in pandemic 2009 influenza a (H1N1) infection: Implications for triage in primary and secondary care | 2.5 | 29 | Citations (PDF) |
| 314 | Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis | 3.5 | 158 | Citations (PDF) |
| 315 | Are biomarkers additive to pulmonary embolism severity index for severity assessment in normotensive patients with acute pulmonary embolism? | 0.3 | 30 | Citations (PDF) |
| 316 | Investigation of "non-responding" presumed lower respiratory tract infection in primary care | 0.1 | 7 | Citations (PDF) |
| 317 | A Randomized Controlled Trial of Nebulized Gentamicin in Non–Cystic Fibrosis Bronchiectasis | 5.0 | 283 | Citations (PDF) |
| 318 | Impact of mannose-binding lectin insufficiency on the course of cystic fibrosis: A review and meta-analysis | 1.5 | 78 | Citations (PDF) |
| 319 | Authors' response | 3.4 | 0 | Citations (PDF) |
| 320 | Safety and efficacy of CURB65-guided antibiotic therapy in community-acquired pneumonia | 2.1 | 49 | Citations (PDF) |
| 321 | Increasing outpatient treatment of mild community-acquired pneumonia: systematic review and meta-analysis | 6.5 | 54 | Citations (PDF) |
| 322 | Predicting mortality with severity assessment tools in out-patients with community-acquired pneumonia | 0.3 | 36 | Citations (PDF) |
| 323 | Epidemiology, Antibiotic Therapy, and Clinical Outcomes in Health Care-Associated Pneumonia: A UK Cohort Study | 3.7 | 243 | Citations (PDF) |
| 324 | Validation of the Infectious Diseases Society of America/American Thoratic Society Minor Criteria for Intensive Care Unit Admission in Community-Acquired Pneumonia Patients Without Major Criteria or Contraindications to Intensive Care Unit Care | 3.7 | 141 | Citations (PDF) |
| 325 | Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic | 2.1 | 53 | Citations (PDF) |
| 326 | Incidence and Prognostic Implications of Acute Kidney Injury on Admission in Patients With Community-Acquired PneumoniaChest, 2010, 138, 825-832 | 0.8 | 76 | Citations (PDF) |
| 327 | Right ventricular dilation on CT pulmonary angiogram independently predicts mortality in pulmonary embolism | 1.8 | 26 | Citations (PDF) |
| 328 | Statins in community acquired pneumonia: Evidence from experimental and clinical studies | 1.8 | 76 | Citations (PDF) |
| 329 | Severity assessment in community-acquired pneumonia: a review | 0.3 | 81 | Citations (PDF) |
| 330 | Risk factors for complicated parapneumonic effusion and empyema on presentation to hospital with community-acquired pneumonia | 3.4 | 187 | Citations (PDF) |
| 331 | Admission D-dimer Can Identify Low-Risk Patients With Community-Acquired Pneumonia | 1.5 | 58 | Citations (PDF) |
| 332 | ICU admission and severity assessment in community-acquired pneumonia | 4.1 | 35 | Citations (PDF) |
| 333 | The Reply | 1.4 | 0 | Citations (PDF) |
| 334 | The Reply | 1.4 | 0 | Citations (PDF) |
| 335 | C-Reactive Protein Is an Independent Predictor of Severity in Community-acquired Pneumonia | 1.4 | 348 | Citations (PDF) |
| 336 | The Reply | 1.4 | 1 | Citations (PDF) |
| 337 | Prior Statin Use Is Associated with Improved Outcomes in Community-acquired Pneumonia | 1.4 | 165 | Citations (PDF) |
| 338 | The Reply | 1.4 | 0 | Citations (PDF) |
| 339 | Predicting the Need for Mechanical Ventilation and/or Inotropic Support for Young Adults Admitted to the Hospital with Community‐Acquired Pneumonia | 3.7 | 68 | Citations (PDF) |
| 340 | Systolic blood pressure is superior to other haemodynamic predictors of outcome in community acquired pneumonia | 3.4 | 84 | Citations (PDF) |
| 341 | A Powerful New Severity Score for Community‐Acquired Pneumonia But Will Anyone Use It? | 3.7 | 3 | Citations (PDF) |
| 342 | Pulmonary arterial pulse pressure and mortality in pulmonary arterial hypertension | 1.8 | 37 | Citations (PDF) |
| 343 | Antihistamine Drugs in Acute Nephritis | 0.1 | 12 | Citations (PDF) |
| 344 | A Comprehensive Analysis of the Impact of
Pseudomonas aeruginosa
Colonization on Prognosis in Adult Bronchiectasis | 2.1 | 324 | Citations (PDF) |
| 345 | Macrolide antibiotics for non-cystic fibrosis bronchiectasis | 1.7 | 5 | Citations (PDF) |
| 346 | Oral versus inhaled antibiotics for non-cystic fibrosis bronchiectasis | 1.7 | 1 | Citations (PDF) |
| 347 | Continuous versus intermittent antibiotics for non-cystic fibrosis bronchiectasis | 1.7 | 2 | Citations (PDF) |
| 348 | Intermittent prophylactic antibiotics for bronchiectasis | 1.7 | 1 | Citations (PDF) |
| 349 | Brief Clinical Review: Non-Responding Pneumonia | 0.0 | 10 | Citations (PDF) |
| 350 | Neutrophil-derived biomarkers in bronchiectasis: identifying a common therapeutic target | 6.5 | 21 | Citations (PDF) |
| 351 | Bronchiectasis and treatable traits: the journey from concept to clinical practice | 1.8 | 6 | Citations (PDF) |
| 352 | Amikacin liposome inhalation suspension in newly diagnosed
Mycobacterium avium
complex lung disease (ARISE): a 6-month double-blind, active comparator trial | 2.1 | 2 | Citations (PDF) |
| 353 | The
<i>European Respiratory Journal</i>
2026: towards the golden age of respiratory science? | 6.5 | 0 | Citations (PDF) |
| 354 | Understanding risk of poor outcomes in adults hospitalised with respiratory syncytial virus infection: evidence from a multicentre UK cohortThorax, 0, , thorax-2025-224192 | 3.4 | 2 | Citations (PDF) |
| 355 | Clearing the air: Clarifying data and interpretations from the ASPEN trial of brensocatib in bronchiectasis | 6.2 | 0 | Citations (PDF) |
| 356 | Lactate is an independent marker of severity in hospitalised patients with community-acquired pneumonia | 6.5 | 1 | Citations (PDF) |
| 357 | Clostridium difficile
infection following community-acquired pneumonia | 6.5 | 0 | Citations (PDF) |
| 358 | Mannose binding lectin deficiency is associated with disease severity in patients with non-cystic fibrosis bronchiectasis | 6.5 | 0 | Citations (PDF) |
| 359 | Ten unanswered questions about dipeptidyl peptidase-1 inhibition in bronchiectasis | 15.9 | 0 | Citations (PDF) |
| 360 | Simplifying IDSA/ATS pneumonia guidelines | 6.5 | 0 | Citations (PDF) |
| 361 | Low frequency of resistant pathogens in nursing home acquired pneumonia: A prospective study and systematic review | 6.5 | 0 | Citations (PDF) |
| 362 | Reducing inappropriate antibiotic use in lower respiratory tract infection (LRTI); a quality improvement study | 6.5 | 0 | Citations (PDF) |
| 363 | Healthcare associated pneumonia does not accurately identify potentially resistant pathogens: A systematic evaluation | 6.5 | 0 | Citations (PDF) |
| 364 | The impact of bronchiectasis on outcomes in a large cohort of patients hospitalised with exacerbations of COPD | 6.5 | 0 | Citations (PDF) |
| 365 | Patterns of spirometry in bronchiectasis patients and relationship to markers of disease severity and hospitalisation | 6.5 | 0 | Citations (PDF) |
| 366 | Clinical significance of autoantibody screening in patients with idiopathic pulmonary fibrosis | 6.5 | 0 | Citations (PDF) |
| 367 | Impact of hyperglycaemia and comorbid diabetes mellitus on short and long-term outcome after COPD exacerbation | 6.5 | 0 | Citations (PDF) |
| 368 | Severity scores do not accurately predict microbial aetiology in community-acquired pneumonia | 6.5 | 0 | Citations (PDF) |
| 369 | Clinicians demonstrate substantial uncertainty in antibiotic management of HCAP and CAP with immunosuppression- a survey study | 6.5 | 0 | Citations (PDF) |
| 370 | Co-existent rheumatoid arthritis and non-cystic fibrosis bronchiectasis: Evidence for more severe pulmonary disease using the bronchiectasis severity index (BSI) | 6.5 | 0 | Citations (PDF) |
| 371 | Rheumatoid arthritis and bronchiectasis: A multicentre study assessing pulmonary disease severity using the bronchiectasis severity index (BSI) | 6.5 | 0 | Citations (PDF) |
| 372 | Goodbye seems to be the hardest word: long-term macrolide withdrawal in bronchiectasis | 1.6 | 0 | Citations (PDF) |
| 373 | The weight of radiological severity in patients with non-CF bronchiectasis | 6.5 | 0 | Citations (PDF) |
| 374 | A new anti-inflammatory treatment for bronchiectasis: a viewpoint on optimal dose selection for DPP1 inhibition in clinical practice | 5.0 | 0 | Citations (PDF) |
| 375 | Safety and antimicrobial efficacy of CSL787, a novel nebulized IgG therapy, in patients with bronchiectasis: results from a randomized phase 1 trial | 5.0 | 0 | Citations (PDF) |
| 376 | Targeting Inflammation in Bronchiectasis | 8.5 | 1 | Citations (PDF) |
| 377 | The European Respiratory Society guideline for management of adult bronchiectasis: clinical summary | 1.8 | 1 | Citations (PDF) |
| 378 | The European respiratory society guideline for adult bronchiectasis 2025: summary and implementation guide for primary care | 2.3 | 0 | Citations (PDF) |
| 379 | The importance of symptoms in bronchiectasis | 4.7 | 1 | Citations (PDF) |
| 380 | Increased Neutrophil Elastase in Affected Lobes of Bronchiectasis and Correlation of Its Levels between Sputum and Bronchial Lavage Fluid | 0.0 | 0 | Citations (PDF) |
| 381 | COS we can – should we? Core outcome sets and pneumonia | 6.5 | 0 | Citations (PDF) |
| 382 | Neutrophil elastase activity in bronchial lavage fluid and the one-year follow-up outcomes in bronchiectasis patients: A multicenter prospective cohort study | 1.5 | 0 | Citations (PDF) |
